Relapsing remitting multiple sclerosis Trials in Ufa, Russia
Conditions / Relapsing remitting multiple sclerosis / Ufa, Russia
Relapsing remitting multiple sclerosis has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02255656 | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 | COMPLETED | PHASE4 |
| NCT00870740 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 |
| NCT01578785 | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | PHASE3 |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | COMPLETED | PHASE3 |
| NCT01963611 | Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) | TERMINATED | PHASE2 |
| NCT00390221 | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT01051349 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE2 |
| NCT01534182 | Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) | COMPLETED | PHASE4 |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 |